What you should know:
– PreciseDx®a leader in Powered by AI diagnostics for oncology, announces a crucial collaboration with UCLA Department of Pathology and Laboratory Medicine.
– The research initiative focuses on evaluating PreciseDx’s innovative tool, PreciseBreast™, for its ability to accurately assess recurrence risk in patients diagnosed with triple negative breast cancer (TNBC).
Why focus on triple negative breast cancer?
- TNBC Challenges: Representing only 10 to 20% of breast cancer cases, TNBC is particularly aggressive and carries a higher risk of recurrence. It is often linked to younger women, BRCA1/2 gene mutations, and ethnic/racial disparities. Traditional treatments offer limited effectiveness.
- Need advanced tools: Recent discoveries of TNBC subtypes and the potential of immunotherapy highlight the urgent need for more sophisticated tools for TNBC categorization and risk assessment. This is crucial for developing personalized treatment plans and improving patient outcomes.
Building on previous successes
This new study expands on an earlier subgroup analysis of TNBC patients from the PreciseBreast-Mount Sinai Hospital Validation Study. UCLA’s participation allows for the evaluation of a larger, well-annotated TNBC cohort from the UCLA Health System.
The power of AI and collaboration
The collaborative study integrates cutting-edge AI algorithms with comprehensive clinical data. The objective is to validate PreciseBreast™ as a reliable digital breast cancer test for:
- Improved early detection: PreciseBreast™ aims to identify TNBC recurrence at an earlier stage, enabling rapid intervention.
- Personalized treatment strategies: This AI-powered tool can potentially support the development of individualized treatment plans based on the specific needs of each patient.
